ID   I23O1_HUMAN             Reviewed;         403 AA.
AC   P14902; E5RGR8; F6M9T7; Q540B4;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   15-MAR-2017, entry version 160.
DE   RecName: Full=Indoleamine 2,3-dioxygenase 1;
DE            Short=IDO-1;
DE            EC=1.13.11.52 {ECO:0000269|PubMed:17671174};
DE   AltName: Full=Indoleamine-pyrrole 2,3-dioxygenase;
GN   Name=IDO1; Synonyms=IDO, INDO;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION BY IFNG.
RC   TISSUE=Fibroblast;
RX   PubMed=2109605; DOI=10.1016/0006-291X(90)91666-G;
RA   Dai W., Gupta S.L.;
RT   "Molecular cloning, sequencing and expression of human interferon-
RT   gamma-inducible indoleamine 2,3-dioxygenase cDNA.";
RL   Biochem. Biophys. Res. Commun. 168:1-8(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Lung;
RX   PubMed=2326172; DOI=10.1093/nar/18.2.367;
RA   Tone S., Takikawa O., Habara-Ohkubo A., Kadoya A., Yoshida R.,
RA   Kido R.;
RT   "Primary structure of human indoleamine 2,3-dioxygenase deduced from
RT   the nucleotide sequence of its cDNA.";
RL   Nucleic Acids Res. 18:367-367(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1449503; DOI=10.1016/0006-291X(92)91590-M;
RA   Kadoya A., Tone S., Maeda H., Minatogawa Y., Kido R.;
RT   "Gene structure of human indoleamine 2,3-dioxygenase.";
RL   Biochem. Biophys. Res. Commun. 189:530-536(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Peripheral blood;
RA   He X., Xu L., Liu Y., Zeng Y.;
RT   "Human indoleamine 2,3-dioxygenase from peripheral blood.";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RA   Qureshi A.M., Asghar K., Ashiq T., Anwar A., Raza M.I., Noor F.,
RA   Qadri I.;
RT   "Cloning and expression of human indolamine 2,3 dioxygenase.";
RL   Submitted (APR-2011) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   REVIEW, AND INDUCTION BY IFNG.
RX   PubMed=1907934;
RA   Taylor M.W., Feng G.S.;
RT   "Relationship between interferon-gamma, indoleamine 2,3-dioxygenase,
RT   and tryptophan catabolism.";
RL   FASEB J. 5:2516-2522(1991).
RN   [10]
RP   FUNCTION.
RX   PubMed=14502282; DOI=10.1038/nm934;
RA   Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D.,
RA   Parmentier N., Boon T., Van den Eynde B.J.;
RT   "Evidence for a tumoral immune resistance mechanism based on
RT   tryptophan degradation by indoleamine 2,3-dioxygenase.";
RL   Nat. Med. 9:1269-1274(2003).
RN   [11]
RP   COFACTOR.
RX   PubMed=16574111; DOI=10.1016/j.febslet.2006.03.034;
RA   Vottero E., Mitchell D.A., Page M.J., MacGillivray R.T.,
RA   Sadowski I.J., Roberge M., Mauk A.G.;
RT   "Cytochrome b(5) is a major reductant in vivo of human indoleamine
RT   2,3-dioxygenase expressed in yeast.";
RL   FEBS Lett. 580:2265-2268(2006).
RN   [12]
RP   FUNCTION, ENZYME REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=17671174; DOI=10.1158/0008-5472.CAN-07-1872;
RA   Metz R., Duhadaway J.B., Kamasani U., Laury-Kleintop L., Muller A.J.,
RA   Prendergast G.C.;
RT   "Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical
RT   target of the antitumor indoleamine 2,3-dioxygenase inhibitory
RT   compound D-1-methyl-tryptophan.";
RL   Cancer Res. 67:7082-7087(2007).
RN   [13]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=18026683; DOI=10.1007/s00239-007-9049-1;
RA   Yuasa H.J., Takubo M., Takahashi A., Hasegawa T., Noma H., Suzuki T.;
RT   "Evolution of vertebrate indoleamine 2,3-dioxygenases.";
RL   J. Mol. Evol. 65:705-714(2007).
RN   [14]
RP   DIFFERENCE BETWEEN IDO1 AND IDO2.
RX   PubMed=18418598; DOI=10.1007/s00262-008-0513-6;
RA   Loeb S., Koenigsrainer A., Zieker D., Bruecher B.L., Rammensee H.G.,
RA   Opelz G., Terness P.;
RT   "IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-
RT   methyl tryptophan inhibits tryptophan catabolism.";
RL   Cancer Immunol. Immunother. 58:153-157(2009).
RN   [15]
RP   DIFFERENCE BETWEEN IDO1 AND IDO2.
RX   PubMed=25394548; DOI=10.1038/emm.2014.69;
RA   Lee Y.K., Lee H.B., Shin D.M., Kang M.J., Yi E.C., Noh S., Lee J.,
RA   Lee C., Min C.K., Choi E.Y.;
RT   "Heme-binding-mediated negative regulation of the tryptophan metabolic
RT   enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2.";
RL   Exp. Mol. Med. 46:E121-E121(2014).
RN   [16]
RP   DIFFERENCE BETWEEN IDO1 AND IDO2.
RX   PubMed=25950090; DOI=10.1111/febs.13316;
RA   Yuasa H.J., Mizuno K., Ball H.J.;
RT   "Low efficiency IDO2 enzymes are conserved in lower vertebrates,
RT   whereas higher efficiency IDO1 enzymes are dispensable.";
RL   FEBS J. 282:2735-2745(2015).
RN   [17]
RP   TISSUE SPECIFICITY.
RX   PubMed=26155395; DOI=10.1080/2162402X.2014.1003012;
RA   Vigneron N., van Baren N., Van den Eynde B.J.;
RT   "Expression profile of the human IDO1 protein, a cancer drug target
RT   involved in tumoral immune resistance.";
RL   OncoImmunology 4:E1003012-E1003012(2015).
RN   [18]
RP   REVIEW.
RX   PubMed=23103127; DOI=10.1016/j.it.2012.10.001;
RA   Munn D.H., Mellor A.L.;
RT   "Indoleamine 2,3 dioxygenase and metabolic control of immune
RT   responses.";
RL   Trends Immunol. 34:137-143(2013).
RN   [19]
RP   REVIEW.
RX   PubMed=25157255; DOI=10.3389/fimmu.2014.00384;
RA   Schmidt S.V., Schultze J.L.;
RT   "New insights into IDO biology in bacterial and viral infections.";
RL   Front. Immunol. 5:384-384(2014).
RN   [20]
RP   REVIEW, AND TISSUE SPECIFICITY.
RX   PubMed=25691885; DOI=10.3389/fimmu.2015.00034;
RA   van Baren N., Van den Eynde B.J.;
RT   "Tryptophan-degrading enzymes in tumoral immune resistance.";
RL   Front. Immunol. 6:34-34(2015).
RN   [21]
RP   REVIEW.
RX   PubMed=25970480; DOI=10.1021/acs.jmedchem.5b00326;
RA   Roehrig U.F., Majjigapu S.R., Vogel P., Zoete V., Michielin O.;
RT   "Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1)
RT   inhibitors.";
RL   J. Med. Chem. 58:9421-9437(2015).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) IN COMPLEX WITH HEME, AND
RP   COFACTOR.
RX   PubMed=16477023; DOI=10.1073/pnas.0508996103;
RA   Sugimoto H., Oda S., Otsuki T., Hino T., Yoshida T., Shiro Y.;
RT   "Crystal structure of human indoleamine 2,3-dioxygenase: catalytic
RT   mechanism of O2 incorporation by a heme-containing dioxygenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:2611-2616(2006).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.79 ANGSTROMS) IN COMPLEX WITH HEME, AND
RP   COFACTOR.
RX   PubMed=25313323; DOI=10.1021/ml500247w;
RA   Tojo S., Kohno T., Tanaka T., Kamioka S., Ota Y., Ishii T.,
RA   Kamimoto K., Asano S., Isobe Y.;
RT   "Crystal structures and structure-activity relationships of
RT   imidazothiazole derivatives as IDO1 inhibitors.";
RL   ACS Med. Chem. Lett. 5:1119-1123(2014).
CC   -!- FUNCTION: Catalyzes the first and rate limiting step of the
CC       catabolism of the essential amino acid tryptophan along the
CC       kynurenine pathway (PubMed:17671174). Involved in the peripheral
CC       immune tolerance, contributing to maintain homeostasis by
CC       preventing autoimmunity or immunopathology that would result from
CC       uncontrolled and overreacting immune responses (PubMed:25691885).
CC       Tryptophan shortage inhibits T lymphocytes division and
CC       accumulation of tryptophan catabolites induces T-cell apoptosis
CC       and differentiation of regulatory T-cells (PubMed:25691885). Acts
CC       as a suppressor of anti-tumor immunity (PubMed:23103127,
CC       PubMed:25157255, PubMed:14502282, PubMed:25691885). Limits the
CC       growth of intracellular pathogens by depriving tryptophan
CC       (PubMed:25691885). Protects the fetus from maternal immune
CC       rejection (PubMed:25691885). {ECO:0000269|PubMed:14502282,
CC       ECO:0000269|PubMed:17671174, ECO:0000303|PubMed:23103127,
CC       ECO:0000303|PubMed:25157255, ECO:0000303|PubMed:25691885}.
CC   -!- CATALYTIC ACTIVITY: D-tryptophan + O(2) = N-formyl-D-kynurenine.
CC       {ECO:0000269|PubMed:17671174}.
CC   -!- CATALYTIC ACTIVITY: L-tryptophan + O(2) = N-formyl-L-kynurenine.
CC       {ECO:0000269|PubMed:17671174}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000269|PubMed:16477023,
CC         ECO:0000269|PubMed:25313323};
CC       Note=Binds 1 heme group per subunit (PubMed:16477023,
CC       PubMed:25313323). In the active form, the heme iron is in its
CC       ferrous state Fe(+2). The catalytic cycle does not alter the
CC       oxidation state of the heme, but IDO1 is prone to autoxidation
CC       (PubMed:16574111). {ECO:0000269|PubMed:16477023,
CC       ECO:0000269|PubMed:16574111, ECO:0000269|PubMed:25313323};
CC   -!- ENZYME REGULATION: Activity is inhibited by and MTH-trp
CC       (methylthiohydantoin-DL-tryptophan), modestly inhibited by L-1MT
CC       (1-methyl-L-tryptophan) but not D-1MT (1-methyl-D-tryptophan).
CC       {ECO:0000269|PubMed:17671174}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=21.23 uM for L-tryptophan {ECO:0000269|PubMed:18026683};
CC         KM=4.6 mM for D-tryptophan {ECO:0000269|PubMed:18026683};
CC         Note=Catalytic efficiency for L-tryptophan is 150 times higher
CC         than for D-tryptophan.;
CC   -!- PATHWAY: Amino-acid degradation; L-tryptophan degradation via
CC       kynurenine pathway; L-kynurenine from L-tryptophan: step 1/2.
CC   -!- SUBUNIT: Monomer. {ECO:0000303|PubMed:25691885}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:P28776, ECO:0000303|PubMed:25691885}.
CC   -!- TISSUE SPECIFICITY: Expressed in mature dendritic cells located in
CC       lymphoid organs (including lymph nodes, spleen, tonsils, Peyers's
CC       patches, the gut lamina propria, and the thymic medulla), in some
CC       epithelial cells of the female genital tract, as well as in
CC       endothelial cells of term placenta and in lung parenchyma
CC       (PubMed:25691885). Weakly or not expressed in most normal tissues,
CC       but mostly inducible in most tissues (PubMed:25691885). Expressed
CC       in more than 50% of tumors, either by tumoral, stromal, or
CC       endothelial cells (expression in tumor is associated with a worse
CC       clinical outcome) (PubMed:18418598). Not overexpressed in tumor-
CC       draining lymph nodes (PubMed:26155395, PubMed:25691885).
CC       {ECO:0000269|PubMed:18418598, ECO:0000269|PubMed:25691885,
CC       ECO:0000269|PubMed:26155395}.
CC   -!- INDUCTION: By IFNG/IFN-gamma in most cells (PubMed:2109605,
CC       PubMed:1907934). Exogenous inflammatory stimuli induce the
CC       expression of IDO1 in antigen-presenting cells such as dendritic
CC       cells, macrophages and B-cells (PubMed:25157255).
CC       {ECO:0000269|PubMed:2109605, ECO:0000303|PubMed:1907934,
CC       ECO:0000303|PubMed:25157255}.
CC   -!- MISCELLANEOUS: IDO1 is the target for therapy in a range of
CC       clinical settings, including cancer, chronic infections,
CC       autoimmune and allergic syndromes, and transplantation.
CC       {ECO:0000303|PubMed:25970480}.
CC   -!- MISCELLANEOUS: IDO1 and IDO2 are 2 distinct enzymes which catalyze
CC       the same reaction. IDO2 affinity for tryptophan is much lower than
CC       that of IDO1. 50% of Caucasians harbor polymorphisms which abolish
CC       IDO2 enzymatic activity. IDO2 is expressed in human tumors in an
CC       inactive form: tryptophan degradation is entirely provided by IDO1
CC       in these cells (PubMed:18418598). IDO2 may play a role as a
CC       negative regulator of IDO1 by competing for heme-binding with IDO1
CC       (PubMed:25394548). Low efficiency IDO2 enzymes have been conserved
CC       throughout vertebrate evolution, whereas higher efficiency IDO1
CC       enzymes are dispensable in many lower vertebrate lineages
CC       (PubMed:25950090). IDO1 may have arisen by gene duplication of a
CC       more ancient proto-IDO gene before the divergence of marsupial and
CC       eutherian (placental) mammals. {ECO:0000269|PubMed:18418598,
CC       ECO:0000269|PubMed:25394548, ECO:0000269|PubMed:25950090}.
CC   -!- MISCELLANEOUS: Elevated IDO1 expression is a hallmark of major
CC       viral infections including HIV, HBV, HCV or influenza and also of
CC       major bacteria infections, such as Tb, CAP, listeriosis and
CC       sepsis. Depletion of tryptophan and production of tryptophan
CC       metabolites with bactericidal activity are important as direct
CC       anti-pathogen mechanisms. Pathogens are able to highjack the
CC       immunosuppressive effects of IDO1 and make use of them to
CC       facilitate their own life cycle. {ECO:0000303|PubMed:25157255}.
CC   -!- SIMILARITY: Belongs to the indoleamine 2,3-dioxygenase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AC007991; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IDO1ID40973ch8p11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M34455; AAA36081.1; -; mRNA.
DR   EMBL; X17668; CAA35663.1; -; mRNA.
DR   EMBL; M86472; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M86473; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M86474; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M86475; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M86476; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M86477; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M86478; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M86479; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M86480; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M86481; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; JF772862; AEF30540.1; -; mRNA.
DR   EMBL; AY221100; AAO34405.1; -; mRNA.
DR   EMBL; AK313259; BAG36069.1; -; mRNA.
DR   EMBL; AC007991; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC027882; AAH27882.1; -; mRNA.
DR   CCDS; CCDS47847.1; -.
DR   PIR; PC1161; PC1161.
DR   RefSeq; NP_002155.1; NM_002164.5.
DR   UniGene; Hs.840; -.
DR   PDB; 2D0T; X-ray; 2.30 A; A/B=1-403.
DR   PDB; 2D0U; X-ray; 3.40 A; A/B=1-403.
DR   PDB; 4PK5; X-ray; 2.79 A; A/B=1-403.
DR   PDB; 4PK6; X-ray; 3.45 A; A/B=1-403.
DR   PDB; 4U72; X-ray; 2.00 A; A/B=1-403.
DR   PDB; 4U74; X-ray; 2.31 A; A/B=1-403.
DR   PDB; 5EK2; X-ray; 2.68 A; A/B=1-403.
DR   PDB; 5EK3; X-ray; 2.21 A; A/B=1-403.
DR   PDB; 5EK4; X-ray; 2.64 A; A/B=1-403.
DR   PDB; 5ETW; X-ray; 2.70 A; A/B=1-403.
DR   PDBsum; 2D0T; -.
DR   PDBsum; 2D0U; -.
DR   PDBsum; 4PK5; -.
DR   PDBsum; 4PK6; -.
DR   PDBsum; 4U72; -.
DR   PDBsum; 4U74; -.
DR   PDBsum; 5EK2; -.
DR   PDBsum; 5EK3; -.
DR   PDBsum; 5EK4; -.
DR   PDBsum; 5ETW; -.
DR   ProteinModelPortal; P14902; -.
DR   SMR; P14902; -.
DR   BioGrid; 109832; 3.
DR   IntAct; P14902; 4.
DR   MINT; MINT-1414454; -.
DR   STRING; 9606.ENSP00000430505; -.
DR   BindingDB; P14902; -.
DR   ChEMBL; CHEMBL4685; -.
DR   DrugBank; DB00150; L-Tryptophan.
DR   DrugBank; DB01065; Melatonin.
DR   GuidetoPHARMACOLOGY; 2829; -.
DR   iPTMnet; P14902; -.
DR   PhosphoSitePlus; P14902; -.
DR   BioMuta; IDO1; -.
DR   DMDM; 123948; -.
DR   EPD; P14902; -.
DR   PaxDb; P14902; -.
DR   PeptideAtlas; P14902; -.
DR   PRIDE; P14902; -.
DR   DNASU; 3620; -.
DR   Ensembl; ENST00000518237; ENSP00000430950; ENSG00000131203.
DR   Ensembl; ENST00000522495; ENSP00000430505; ENSG00000131203.
DR   GeneID; 3620; -.
DR   KEGG; hsa:3620; -.
DR   UCSC; uc003xnm.5; human.
DR   UCSC; uc064mfy.1; human.
DR   CTD; 3620; -.
DR   DisGeNET; 3620; -.
DR   GeneCards; IDO1; -.
DR   HGNC; HGNC:6059; IDO1.
DR   HPA; HPA023072; -.
DR   HPA; HPA023149; -.
DR   HPA; HPA027772; -.
DR   MIM; 147435; gene.
DR   neXtProt; NX_P14902; -.
DR   OpenTargets; ENSG00000131203; -.
DR   PharmGKB; PA29869; -.
DR   eggNOG; ENOG410IGEY; Eukaryota.
DR   eggNOG; ENOG410XQHE; LUCA.
DR   GeneTree; ENSGT00390000002154; -.
DR   HOGENOM; HOG000203926; -.
DR   HOVERGEN; HBG006100; -.
DR   InParanoid; P14902; -.
DR   KO; K00463; -.
DR   OMA; EAYDACV; -.
DR   OrthoDB; EOG091G0DCU; -.
DR   PhylomeDB; P14902; -.
DR   TreeFam; TF330978; -.
DR   BioCyc; MetaCyc:HS05502-MONOMER; -.
DR   BRENDA; 1.13.11.11; 2681.
DR   BRENDA; 1.13.11.52; 2681.
DR   Reactome; R-HSA-71240; Tryptophan catabolism.
DR   SABIO-RK; P14902; -.
DR   UniPathway; UPA00333; UER00453.
DR   ChiTaRS; IDO1; human.
DR   EvolutionaryTrace; P14902; -.
DR   GeneWiki; Indoleamine_2,3-dioxygenase; -.
DR   GenomeRNAi; 3620; -.
DR   PRO; PR:P14902; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000131203; -.
DR   ExpressionAtlas; P14902; baseline and differential.
DR   Genevisible; P14902; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030485; C:smooth muscle contractile fiber; IEA:Ensembl.
DR   GO; GO:0032421; C:stereocilium bundle; IEA:Ensembl.
DR   GO; GO:0009055; F:electron carrier activity; TAS:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0033754; F:indoleamine 2,3-dioxygenase activity; IMP:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004833; F:tryptophan 2,3-dioxygenase activity; EXP:Reactome.
DR   GO; GO:0002534; P:cytokine production involved in inflammatory response; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; TAS:ProtInc.
DR   GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW.
DR   GO; GO:0034276; P:kynurenic acid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0033555; P:multicellular organismal response to stress; IEA:Ensembl.
DR   GO; GO:0032693; P:negative regulation of interleukin-10 production; IEA:Ensembl.
DR   GO; GO:0070233; P:negative regulation of T cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0002678; P:positive regulation of chronic inflammatory response; IEA:Ensembl.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IEA:Ensembl.
DR   GO; GO:0070234; P:positive regulation of T cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0002666; P:positive regulation of T cell tolerance induction; IEA:Ensembl.
DR   GO; GO:0002830; P:positive regulation of type 2 immune response; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0036269; P:swimming behavior; IEA:Ensembl.
DR   GO; GO:0006569; P:tryptophan catabolic process; TAS:Reactome.
DR   GO; GO:0019441; P:tryptophan catabolic process to kynurenine; IEA:UniProtKB-UniPathway.
DR   InterPro; IPR000898; Indolamine_dOase.
DR   Pfam; PF01231; IDO; 1.
DR   PROSITE; PS00876; IDO_1; 1.
DR   PROSITE; PS00877; IDO_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasm; Dioxygenase;
KW   Direct protein sequencing; Heme; Immunity; Iron; Metal-binding;
KW   Oxidoreductase; Polymorphism; Reference proteome;
KW   Tryptophan catabolism.
FT   CHAIN         1    403       Indoleamine 2,3-dioxygenase 1.
FT                                /FTId=PRO_0000215204.
FT   METAL       346    346       Iron (heme proximal ligand).
FT                                {ECO:0000244|PDB:2D0T,
FT                                ECO:0000244|PDB:2D0U,
FT                                ECO:0000244|PDB:4PK5,
FT                                ECO:0000244|PDB:4PK6,
FT                                ECO:0000269|PubMed:16477023,
FT                                ECO:0000269|PubMed:25313323}.
FT   VARIANT       4      4       A -> T (in dbSNP:rs35059413).
FT                                /FTId=VAR_053368.
FT   CONFLICT    251    251       G -> R (in Ref. 5; AEF30540).
FT                                {ECO:0000305}.
FT   HELIX        13     15       {ECO:0000244|PDB:4U72}.
FT   TURN         19     21       {ECO:0000244|PDB:4U72}.
FT   HELIX        34     36       {ECO:0000244|PDB:4U72}.
FT   HELIX        37     44       {ECO:0000244|PDB:4U72}.
FT   HELIX        46     51       {ECO:0000244|PDB:4U72}.
FT   HELIX        55     61       {ECO:0000244|PDB:4U72}.
FT   HELIX        67     69       {ECO:0000244|PDB:4U72}.
FT   HELIX        73     92       {ECO:0000244|PDB:4U72}.
FT   STRAND       95     97       {ECO:0000244|PDB:4U72}.
FT   STRAND      101    103       {ECO:0000244|PDB:4U72}.
FT   HELIX       105    118       {ECO:0000244|PDB:4U72}.
FT   HELIX       126    129       {ECO:0000244|PDB:4U72}.
FT   TURN        130    132       {ECO:0000244|PDB:4U72}.
FT   STRAND      135    138       {ECO:0000244|PDB:4U72}.
FT   HELIX       145    147       {ECO:0000244|PDB:4U72}.
FT   STRAND      148    151       {ECO:0000244|PDB:2D0T}.
FT   HELIX       160    178       {ECO:0000244|PDB:4U72}.
FT   HELIX       181    189       {ECO:0000244|PDB:4U72}.
FT   HELIX       193    214       {ECO:0000244|PDB:4U72}.
FT   HELIX       217    220       {ECO:0000244|PDB:4U72}.
FT   HELIX       223    228       {ECO:0000244|PDB:4U72}.
FT   HELIX       230    233       {ECO:0000244|PDB:4U72}.
FT   STRAND      237    239       {ECO:0000244|PDB:4U72}.
FT   HELIX       241    243       {ECO:0000244|PDB:4U72}.
FT   STRAND      247    249       {ECO:0000244|PDB:4U72}.
FT   TURN        250    252       {ECO:0000244|PDB:4U72}.
FT   STRAND      254    257       {ECO:0000244|PDB:5EK3}.
FT   HELIX       264    266       {ECO:0000244|PDB:4U72}.
FT   HELIX       268    276       {ECO:0000244|PDB:4U72}.
FT   STRAND      284    286       {ECO:0000244|PDB:4U72}.
FT   HELIX       287    295       {ECO:0000244|PDB:4U72}.
FT   HELIX       296    298       {ECO:0000244|PDB:4U72}.
FT   HELIX       301    311       {ECO:0000244|PDB:4U72}.
FT   HELIX       316    321       {ECO:0000244|PDB:4U72}.
FT   TURN        322    324       {ECO:0000244|PDB:5EK3}.
FT   HELIX       326    353       {ECO:0000244|PDB:4U72}.
FT   HELIX       355    360       {ECO:0000244|PDB:4U72}.
FT   HELIX       381    397       {ECO:0000244|PDB:4U72}.
SQ   SEQUENCE   403 AA;  45326 MW;  E92CF57AD0D0BA8D CRC64;
     MAHAMENSWT ISKEYHIDEE VGFALPNPQE NLPDFYNDWM FIAKHLPDLI ESGQLRERVE
     KLNMLSIDHL TDHKSQRLAR LVLGCITMAY VWGKGHGDVR KVLPRNIAVP YCQLSKKLEL
     PPILVYADCV LANWKKKDPN KPLTYENMDV LFSFRDGDCS KGFFLVSLLV EIAAASAIKV
     IPTVFKAMQM QERDTLLKAL LEIASCLEKA LQVFHQIHDH VNPKAFFSVL RIYLSGWKGN
     PQLSDGLVYE GFWEDPKEFA GGSAGQSSVF QCFDVLLGIQ QTAGGGHAAQ FLQDMRRYMP
     PAHRNFLCSL ESNPSVREFV LSKGDAGLRE AYDACVKALV SLRSYHLQIV TKYILIPASQ
     QPKENKTSED PSKLEAKGTG GTDLMNFLKT VRSTTEKSLL KEG
//
